BACKGROUND: Women with symptomatic uterine fibroids can report a myriad of symptoms, including pain, bleeding, infertility, and psychosocial sequelae. Optimizing fibroid research requires the ability to enroll populations of women with image-confirmed symptomatic uterine fibroids. OBJECTIVE: Our objective was to develop an electronic health recordebased algorithm to identify women with symptomatic uterine fibroids for a comparative effectiveness study of medical or surgical treatments on quality-of-life measures. Using an iterative process and text-mining techniques, an effective computable phenotype algorithm, composed of demographics, and clinical and laboratory characteristics, was developed with reasonable performance. Such algorithms provide a feasible, efficient way to identify populations of women with symptomatic uterine fibroids for the conduct of large traditional or pragmatic trials and observational comparative effectiveness studies. Symptomatic uterine fibroids, due to menorrhagia, pelvic pain, bulk symptoms, or infertility, are a source of substantial morbidity for reproductive-age women. Comparing Treatment Options for Uterine Fibroids is a multisite registry study to compare the effectiveness of hormonal or surgical fibroid treatments on women's perceptions of their quality of life. Electronic health recordebased algorithms are able to identify large numbers of women with fibroids, but additional work is needed to develop electronic health record algorithms that can identify women with symptomatic fibroids to optimize fibroid research. We sought to develop an efficient electronic health recordebased algorithm that can identify women with symptomatic uterine fibroids in a large health care system for recruitment into largescale observational and interventional research in fibroid management. STUDY DESIGN: We developed and assessed the accuracy of 3 algorithms to identify patients with symptomatic fibroids using an iterative approach. The data source was the Carolina Data Warehouse for Health, a repository for the health system's electronic health record data. In addition to
Introduction
While electronic health records (EHRs) were launched initially for improvement and transferability of patient care documentation and billing, there has been growing interest from hospital leaders, federal agencies, and researchers to maximize use of EHRs for clinical research. Recent attention by researchers 1, 2 and federal funders 3 has focused on the use of EHRs to speed or enhance participant recruitment, particularly for large pragmatic trials that focus on a broad range of diseases or conditions, prospective comparative effectiveness studies, and rare diseases or clinical conditions for which there is limited evidence on treatment effectiveness. 4 Uterine fibroids (also referred to as leiomyomas or myomas) are common, benign tumors of the uterus, reported in 60-80% of reproductive-age women. 5 The majority of women with fibroids are asymptomatic, but about 20% of women can experience menorrhagia, pelvic pain, bulk symptoms (ie, pelvic pressure or genitourinary symptoms) or infertility. 6 Fibroid symptoms can have a substantial impact on women's daily Original Research ajog.org activities, reducing their quality of life and posing a significant emotional burden. 7, 8 Despite the prevalence and burden of uterine fibroids, there is limited population-based research on the comparative effectiveness of medical vs surgical treatments. In response to this knowledge gap of treatment effectiveness, the Agency for Healthcare Research and Quality 9 and the Patient-Centered Outcomes Research Institute issued a report 10 and priority agenda for comparative effectiveness research in uterine fibroids. Part of this research agenda includes a national registry of women with symptomatic uterine fibroids and the conduct of large, prospective studies to compare patient-centered outcomes among women undergoing medical and surgical treatments. 5 The report also highlighted current limitations in using administrative data to identify symptomatic patients for registry-based fibroid research and women's population health.
The 
Materials and Methods
Three EHR-based algorithms were developed and refined to identify women with symptomatic uterine fibroids using data from the UNC Health Care System from April 4, 2014, through Oct. 1, 2015. This is a large, not-for-profit integrated academic health system in central North Carolina and provides care to a large, diverse population of patients across socioeconomic strata. The institutional review board at UNC approved the study. Below, we describe the data sources and summarize the steps taken to develop and assess the performance of each algorithm.
Data sources
Two sources of data were utilized from the Carolina Data Warehouse for Health, 13 a central data source containing clinical, laboratory, and administrative billing data for patients seen within the UNC Health Care System. Data from UNC EHRs are transferred to the Carolina Data Warehouse for Health and updated on a nightly basis. We used the following data sources: 1) Clinical EHR data included demographics (ie, age), patient problem lists, laboratory test results, ultrasound and magnetic resonance imaging (MRI) reports, outpatient and inpatient visits and the type of outpatient visits (eg, radiology, medical, or emergency department), and medications. The patient problem list included the International Classification of Diseases, Ninth Revision (ICD-9) Clinical Modification (CM) codes for current and past conditions. 2) Billing data included ICD-9-CM diagnosis codes for uterine fibroids, Original Research GYNECOLOGY ajog.org ICD-9-CM procedure codes, and Current Procedural Terminology (CPT) codes for outpatient, inpatient, and emergency department visits.
Study population and definition of symptomatic fibroids
We used the same inclusion criteria to define the study population as those used for the COMPARE-UF study: nonpregnant women, ages 18-54 years, with ultrasound or MRI that suggests the presence of !1 fibroids, symptomatic uterine fibroids, and no history of hysterectomy. Because the purpose of COMPARE-UF is to assess outcomes after surgical or medical treatment of fibroids, participants were required to have an intact uterus with at least 1 imageconfirmed fibroid. The gold standard diagnostic modality for fibroids is grayscale ultrasound, followed by MRI.
14 There are currently no gold standard criteria to define symptomatic fibroids. For this study, we considered a patient as having symptomatic fibroids if there was EHR documentation of the symptoms of bleeding, pain, bulk symptoms, or infertility, all of which are consistent with the definition of symptomatic uterine fibroids for inclusion in the COMPARE-UF registry.
Algorithm development
Algorithms were developed in an iterative fashion (Figure) using a combination of demographic inclusion criteria, ICD-9-CM and CPT codes (Table 1) , clinical data, and key words related to fibroids from clinical notes and imaging reports, to identify women with symptomatic fibroids. For each of the developed algorithms, key word searches for "positive" or "negative" mention of fibroid-related terms ("fibroid," "leiomyoma," or "myomata") within specific reports were made using text-mining techniques. Python coding (Python Software Foundation, Wilmington, DE) was used to search for negative text terms defined as negators (eg, "without evidence," "no evidence") before each of the key terms.
Validation
Algorithms were validated in an iterative fashion as they were developed using expert review of randomly selected subsets of charts. Charts were viewed sequentially by a doctoral-level researcher (S.R.H.) and an obstetrics/gynecology clinician researcher with clinical experience in uterine fibroids (W.K.N.) reviewer. A third clinician reviewer (J.R.H.) was available to render a final decision if the first 2 reviewers were unable to reach a consensus on symptom status. Women were considered positive for symptomatic fibroids if they met any of the following criteria: (1) clinician documentation in the medical record stating that the patient had "symptomatic fibroids" or "fibroids causing symptoms" or otherwise described the case with definitive language indicating that the patient had fibroid-related symptoms; (2) current fibroids for which medical treatment was being considered or administered or cases in which surgical management was being planned; or (3) patient had undergone surgical management or additional medical treatment specific to uterine fibroids since the date of the algorithm run.
Algorithm performance
There are no established thresholds for evaluating the performance of automated algorithms for use in populationbased research, particularly for case detection of symptomatic uterine fibroids where there is no gold standard definition of symptomatic fibroid criteria. Our goal was to develop algorithms that were simple, translatable for use in other health care systems, and could yield a maximized PPV. For the purpose of this study, PPV represents the probability that women identified as having symptomatic uterine fibroids based on the algorithm truly have fibroid-related symptoms as determined by the chart review (considered as the true positive), as shown in the equation below:
The Clopper-Pearson method 15 was used to calculate confidence intervals (CI) for binomial proportions.
10 Analyses were conducted using software (SAS 9.3; SAS Institute Inc, Cary, NC).
Results Algorithms
The initial algorithm (algorithm 1) included the following: (1) ages between 18-54 years; (2) either at least 1 ICD-9-CM diagnosis code for uterine fibroids or ultrasound or MRI report with positive mention of fibroids, leiomyoma, or myomata using text mining; and (3) no ICD-9-CM or CPT codes for hysterectomy and no documented surgical history of hysterectomy ( Figure) . Algorithm 1 identified 4342 presumptive cases of symptomatic uterine fibroids ( Table 2 ). Review of a subset of 150 EHRs of the presumptive cases yielded 71 true cases and a PPV of 47% (95% CI, 0.39e0.56). The primary reason for the misclassifications was the incidental finding of uterine fibroids during the clinical workup or treatment of other gynecologic conditions (eg, ovarian cysts, pelvic inflammatory disease), pregnancy, or abdominal pain.
Algorithm 2 ( Figure) was designed to exclude those cases from algorithm 1 that were incidental, asymptomatic fibroids. The inclusion criteria were modified to require that patients have (1) !2 (rather than !1) ICD-9 diagnosis codes for fibroids; and (2) an imaging report with evidence of fibroids. We thought that women with incidental fibroids would not have multiple visits with ICD-9 codes for fibroids. Also, we modified the criteria to include women who had visits with an ICD-9 diagnosis of fibroids during the specified study period (April 4, 2014, through Oct. 1, 2015), but whose imaging reports showing uterine fibroids had occurred up to 1 year prior to the study period.
PPV ¼ patients with symptomatic uterine fibroids by expert chart review patients identified by EHR À based algorithms ajog.org
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Our premise was that women who were symptomatic would have documentation confirming the presence of fibroids over a longer period of time. Algorithm 2 identified 1174 potential cases of symptomatic uterine fibroids. Manual review of a subset of 51 EHRs found that 50 (98%) of the 51 records had image reports that confirmed the presence of uterine fibroids. Manual chart review yielded 30 true cases of symptomatic uterine fibroids, with a PPVof 65% (95% CI, 0.5e0.79). Some cases were misclassified due to fibroids identified during emergency department visits for nongynecologic conditions (eg, trauma) or among pregnant women during routine perinatal ultrasound. These women truly had fibroids, but they were not deemed as symptomatic upon expert manual review. In algorithm 3, we excluded women with incidental fibroids diagnosed during pregnancy. Women who had a positive pregnancy test (laboratory data) within 3 months of the fibroid diagnosis or fibroids detected through prenatal rather than general ultrasound were excluded. In an effort to exclude women with incidental fibroids diagnosed at the time of an emergency department visit or other ambulatory visit for a nongynecologic symptom, we required that women have at least 2 ICD-9 diagnosis codes for fibroids on separate visit (nonemergency department visit) dates.
For algorithm 3, 99% of the charts reviewed contained image documentation of uterine fibroids. After review of 300 EHRs, algorithm 3 had a PPVof 76% (95% CI, 71e81).
Comment
To our knowledge, this is one of the first efforts to develop a computable phenotype to identify women with symptomatic uterine fibroids. Using an iterative process, we refined the algorithms to exclude asymptomatic cases, including incidental fibroids diagnosed during pregnancy, at the time of clinical evaluation of other gynecologic conditions or during nongynecologic-related emergency department evaluations. The final computable phenotype had a PPV of 76%. This performance seems acceptable given that there is no standard clinical variables or laboratory values for identifying symptomatic uterine fibroids. Relying solely on an automated algorithm for symptomatic fibroids may not be possible. However, our purpose was not to use the algorithms exclusively, but rather, as a first step in identifying women with symptomatic uterine fibroids for screening and potential enrollment.
While EHR-derived algorithms to simply identify cases of uterine fibroids have been associated with a sensitivity, specificity, and PPV of >95%, 12 much less is known about the ability of EHR algorithms to discriminate between patients who are symptomatic and patients with asymptomatic, incidentally found fibroids. Our final algorithm has a PPV of 99% for image-confirmed fibroids ( Table 2 ) that is similar to that reported by Feingold-Link and colleagues 12 to identify patients with image-confirmed fibroids in a health system database.
The results of this work can inform the use of EHR data for use in conducting large-scale fibroid research studies. From a clinical perspective, the final algorithm is simple and able to be easily implemented within a health care system for the conduct of large research studies to assess long-term health or treatment outcomes. The final computable phenotyping algorithm can serve as a practical first step in The prevalence of symptomatic fibroids could have affected the PPV of the final algorithm. Patient self-report of fibroid symptoms and the completeness of documentation 18 of symptoms by the clinician are 2 factors that may also have affected the PPV. It is possible that patients with milder symptoms may not have discussed them with their provider. Clinicians may not have clearly documented symptoms if it was not the primary reason for the health care visit or alternatively, if symptoms were part of several reports or inaccurately attributed to other comorbidity.
Strengths of this study include our ability to use a combination of billing and EHR data from a large health care system. Data were obtained from a wellestablished data source warehouse in which prior algorithms have been developed to identify a range of disease conditions for observational studies and registry recruitment. 19 The components of the algorithm are simple and able to be applied to other health care systems.
There are several limitations that deserve attention. The analysis is based, in part, on administrative billing data that may have coding errors. However, fibroids are a common gynecologic problem with diagnosis codes that are used regularly by clinicians. Review of a subset of EHRs found that the majority of women with an ICD-9 diagnosis code for fibroids had image-confirmed fibroids at chart review. Our study was initiated prior to the implementation of International Statistical Classification of Diseases, 10th Revision codes at our institution. We, therefore, maintained a time frame (April 4, 2014, through Oct. 1, 2015) that would maintain consistency in using data that were coded using ICD-9. We developed the algorithms within a single academic health center, which may limit the generalizability of the findings to other academic or community health systems. Coding practices within UNC Health Care System may differ from other academic or community health systems. We plan further testing of the algorithm in our own health system at different time points and in other health organizations to inform refinements for broader use in fibroid research. Finally, we were unable to evaluate algorithm sensitivity and specificity because resource constraints limited our ability to randomly select a new set of charts (w300) from the EHR to reapply our algorithm.
Conclusions
We developed and validated a computable phenotype with a PPV of 76% that can begin to identify women with symptomatic uterine fibroids using a combination of clinical and billing data and expert chart review. This work represents a first step to identify, via an EHR computable phenotype, patients with a highly prevalent condition that is associated with substantial morbidity and lower perceived quality of life. Further, this approach may help to enhance research on the effectiveness of management options, treatment patterns, and long-term outcomes. If EHRs can be used effectively to identify patients with symptomatic disease for enrollment into a research registry to evaluate the clinical and quality-of-life outcomes of a surgical or medical treatment, then clinicians and researchers will have a powerful tool for designing surveillance systems of population health and patient-centered outcomes.
n a Confirmed with expert chart review; b PPV was calculated based on equation: no. of patients with symptomatic uterine fibroids confirmed by expert chart review divided by no. of patients identified by algorithm as having symptomatic uterine fibroids. Chart reviews and PPV calculations were performed for random sample of charts for each algorithm. For algorithms 2 and 3, there were 5 charts that contained insufficient information to determine if confirmed fibroids were symptomatic. These charts were not counted in denominator when calculating PPVs for symptomatic fibroids for each algorithm. 
